Orthomolekulare Therapie beim Fibromyalgiesyndrom

Zusammenfassung

Mikronährstoffe können eine wichtige ergänzende Rolle in der Prävention und der Therapie vieler Krankheiten spielen. Sie beeinflussen neben psychischen Symptomen und Schmerz auch Funktionskreisläufe wie Inflammation, Immunsystem, Energiehaushalt und oxidativen Stress, die beim Fibromyalgiesyndrom (FMS) eine wichtige Rolle spielen. Im Beitrag wird das ganzheitlich orientierte Konzept der Mikronährstoffmedizin zur Behandlung des FMS vorgestellt.

Abstract

Micronutrients can play an important complementary role in the prevention and therapy of many diseases. In addition to psychic symptoms and pain, they also influence functional circuits like inflammation, immune system, energy balance, and oxidative stress, which play an important role in the fibromyalgia syndrome (FMS). In this article, the holistic concept of micronutrient medicine for the treatment of the FMS is presented.

Fibromyalgie - orthomolekulare Therapie - Mikronährstoffe

Fibromyalgia - orthomolecular therapy - micronutrients

Literatur

• 01 Ablin J N. et al . Mechanisms of disease: genetics of fibromyalgia.  Nat Clin Pract Rheumatol. 2006;  2 671-678
• 02 Adam O. et al . Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis.  Rheumatol Int. 2003;  23 27-36
• 03 Akkus S. et al . Levels of lipid peroxidation, nitric oxide, and antioxidant vitamins in plasma of patients with fibromyalgia.  Cell Biochem Funct. 2009;  27 181-185
• 04 Altindag O, Celik H. Total antioxidant capacity and the severity of the pain in patients with fibromyalgia.  Redox Rep. 2006;  11 131-135
• 05 Armstrong D J. et al . Vitamin D deficiency is associated with anxiety and depression in fibromyalgia.  Clin Rheumatol. 2007;  26 551-554
• 06 Arnold J M. Comorbidity of fibromyalgia and psychiatric disorders.  J Clin Psychiatry. 2006;  67 1219-1225
• 07 Bagis S. et al . Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder?.  Rheumatol Int. 2005;  25 188-190
• 08 Bagis S. et al . Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder?.  Rheumatol Int. 2005;  25 188-190
• 09 Bazzichi L. et al . Altered amino acid homeostasis in subjects affected by fibromyalgia.  Clin Biochem. 2009;  42 1064-1070
• 10 Beauchamp G K. et al . Phytochemistry: Ibuprofen-like activity in extra-virgin olive oil.  Nature. 2005;  437 45-46
• 11 Bell K M. et al . S-adenosylmethionine blood levels in major depression: changes with drug treatment.  Acta Neurol Scand Suppl. 1994;  154 15-18
• 12 Bengtsson A. et al . Reduced high-energy phosphate levels in the painful muscles of patients with primary fibromyalgia.  Arthritis Rheum. 1986;  29 817-821
• 13 Blankenhorn G. Clinical effectiveness of Spondyvit (vitamin E) in activated arthroses. A multicenter placebo-controlled double-blind study.  Z Orthop Ihre Grenzgeb. 1986;  124 340-343
• 14 Bradley L A. Pathophysiologic mechanisms of fibromyalgia and its related disorders.  J Clin Psychiatry. 2008;  69 (S 2) 6-13
• 15 Braun A. Pressesprecherin der DGE. Ärztezeitung 19.7.1999
• 16 Buskila D. et al . The genetics of fibromyalgia syndrome.  Pharmacogenomics. 2007;  8 67-74
• 17 Caruso I. et al . Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome.  J Int Med Res. 1990;  18 (3) 201-209
• 18 Caruso I. et al . Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease.  Am J Med. 1987;  83 66-71
• 19 Cohen H. et al . Autonomic dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability.  Arthritis Rheum. 2000;  29 217-227
• 20 Cordero M D. et al . Coenzyme Q10 distribution in blood is altered in patients with fibromyalgia.  Clin Biochem. 2009;  42 732-735
• 21 Cox I M. et al . Red blood cell magnesium and chronic fatigue syndrome.  Lancet. 1991;  337 757-760
• 22 Crofford L J. Neuroendocrine abnormalities in fibromyalgia and related disorders.  Am J Med Sci. 1998;  315 359-366
• 23 Crofford L J. The hypothalamic-pituitary-adrenal stress axis in fibromyalgia and chronic fatigue syndrome.  Z Rheumatol. 1998;  57 (S 2) 67-71
• 24 Cuatrecasas G. et al . Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study.  BMC Musculoskelet Disord. 2007;  8 119
• 25 Curtis C L. et al . Pathologic Indicators of Degradation and Inflammation in Human Osteoarthritic Cartilage Are Abrogated by Expose to n-3 Fatty Acids.  Arthritis & Rheumatism. 2002;  46 1544-1553
• 26 DACH (DGE, ÖGE, SGE, SVE) .Referenzwerte für die Nährstoffzufuhr. 1. Aufl.
• 27 Fava M. et al . Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine.  Psychiatry Res. 1995;  56 295-297
• 28 Goldberg R J. et al . A metaanalysis of the analgetic effects of omega-3-polyunsaturated fatty acid supplementation for inflammatory joint pain.  Pain. 2007;  129 210-223
• 29 Gür A, Oktayoglu P. Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: new concepts in treatment.  Curr Pharm Des. 2008;  14 1274-1294
• 30 Gür A. et al . Cytokines and depression in cases with fibromyalgia.  J Rheumatol. 2002;  29 358-361
• 31 Häuser W. et al . Fibromyalgiesyndrom: Klassifikation, Diagnose und Behandlungsstrategien.  Dtsch Arztebl Int. 2009;  106 383-391
• 32 Jacobsen S. et al . Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation.  Scand J Rheumatol. 1991;  20 294-302
• 33 Jonas W B. et al . The effect of niacinamide on osteoarthritis: a pilot study.  Inflamm Res. 1996;  5 330-334
• 34 Juhl J H. Fibromyalgia and the serotonin pathway.  Altern Med Rev. 1998;  3 367-375
• 35 Kaartinen K. et al . Vegan diet alleviates fibromyalgia symptoms.  Scandinavian Journal of Rheumatology. 2000;  29 308-313
• 36 Kasikcioglu E. et al . Reduced tolerance of exercise in fibromyalgia may be a consequence of impaired microcirculation initiated by deficient action of nitric oxide.  Med Hypotheses. 2006;  66 950-952
• 37 Lister R E. An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome.  J Int Med Res. 2002;  30 195-199
• 38 Lucas H J. et al . Fibromyalgia – New concepts of pathogenesis and treatment.  Int J Immunopathol Pharmacol. 2006;  19 5-9
• 39 Massey P B. Reduction of fibromyalgia symptoms through intravenous nutrient therapy: results of a pilot clinical trial.  Altern Ther Health Med. 2007;  13 32-34
• 40 Mease P. Fibromyalgia syndrome review of clinical presentation, pathogenesis, outcome measures, and treatment.  J Rheumatol. 2006;  75 6-21
• 41 Nemets B. et al . Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder.  Am J Psychiatry. 2002;  159 477-479
• 42 Neustadt J, Pieczenik S R. Medication-induced mitochondrial damage and disease.  Mol Nutr Food Res. 2008;  52 780-788
• 43 Nowak G. et al . Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study.  Pol J Pharmacol. 2003;  55 1143-1147
• 44 Ozgocmen S. et al . Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide.  Rheumatol Int. 2006;  26 585-597
• 45 Ozgocmen S. et al . Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns.  Rheumatol Int. 2006;  26 598-603
• 46 Park J H. et al . Evidence for metabolic abnormalities in the muscles of patients with fibromyalgia.  Curr Rheumatol Rep. 2000;  2 131-140
• 47 Peet M. et al . A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs.  Arch Gen Psychiatry. 2002;  59 913-919
• 48 Pieczenik S R, Neustadt J. Mitochondrial dysfunction and molecular pathways of disease.  Exp Mol Pathol. 2007;  83 84-92
• 49 Plotnikoff G A, Quigley J M. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain.  Mayo Clin Proc. 2003;  78 1463-1470
• 50 Pongratz D E, Späth M. Morphologic aspects of fibromyalgia.  Z Rheumatol. 1998;  57 (S 2) 47-51
• 51 Reinhard P. et al . Selenium status in fibromyalgia.  Toxicol Lett. 1998;  96–97 177-180
• 52 Richards S. et al . BMJ. 2002;  325 185
• 53 Rossini M. et al . Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients.  Clin Exp Rheumatol. 2007;  25 182-188
• 54 Russell I J. Neurohormonal aspects of fibromyalgia syndrome.  Rheum Dis Clinics North Am. 1989;  15 149-168
• 55 Sackner M A. et al . Say NO to fibromyalgia and chronic fatigue syndrome: an alternative and complementary therapy to aerobic exercise.  Med Hypotheses. 2004;  63 118-123
• 56 Sanchez-Villegas A. et al . Long chain omega-3 fatty acids intake, fish consumption and mental disorders in the SUN cohort study.  Eur J Nutr. 2007;  46 337-346
• 57 Sas K. et al . Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.  J Neurol Sci. 2007;  257 221-239
• 58 Scherak O. et al . High dosage vitamin E therapy in patients with activated arthrosis.  Z Rheumatol. 1990;  49 369-373
• 59 Schwarz M J. et al . Evidence for an altered tryptophan metabolism in fibromyalgia.  Neurobiol Dis. 2002;  11 434-442
• 60 Schwarz M J. et al . Evidence for an altered tryptophan metabolism in fibromyalgia.  Neurobiol Dis. 2002;  11 434-442
• 61 Schwarz M J. et al . Relationsship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients.  Neurosci Lett. 1999;  259 196-198
• 62 Sendur O F. et al . Serum antioxidants and nitric oxide levels in fibromyalgia: a controlled study.  Rheumatol Int. 2009;  29 629-633
• 63 Sendur O F. et al . The relationship between serum trace element levels and clinical parameters in patients with fibromyalgia.  Rheumatol Int. 2008;  28 1117-1121
• 64 Sköldstam L. et al . An experimental study of a Mediteranean diet intervention forpatients with rheumatoid arthritis.  Ann Rheum Dis. 2003;  62 (3) 208-214
• 65 Sprott H. et al . Increased DNA fragmentation and ultrastructural changes in fibromyalgic muscle fibres.  Ann Rheum Dis. 2004;  63 245-251
• 66 Su K P. et al . Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial.  Eur Neuropsychopharmacol. 2003;  13 267-271
• 67 Tanriverdi F. et al . The hypothalamo-pituitary-adrenal axis in chronic fatigue syndrome and fibromyalgia syndrome.  Stress. 2007;  10 1-25
• 68 Tarnopolsky M A. The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies.  Adv Drug Deliv Rev. 2008;  60 1561-1567
• 69 van West D, Maes M. Neuroendocrine and immune aspects of fibromyalgia.  BioDrugs. 2001;  15 521-531
• 70 Vetter G. et al . Shortening diclofenac therapy by B vitamins. Results of a randomized double-blind study, diclofenac 50 mg versus diclofenac 50 mg plus B vitamins, in painful spinal diseases with degenerative changes.  Z Rheumatol. 1988;  47 351-362
• 71 Yunus M B. et al . Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study.  J Rheumatol. 1992;  19 90-94

Korrespondenzadresse